Search clinical trials for: ASA404, DMXAA or DXAA

Total 13 results

Novartis Pharmaceuticals

Terminated

A Dose-escalation Pharmacokinetic Study of Intravenous ASA404 in Adult Advanced Cancer Patients With Impaired Renal Function and Patients With Normal Renal Function

Metastatic Cancer

United States
Novartis Pharmaceuticals

Terminated

A Study to Evaluate the Effects of ASA404 Alone or in Combination With Taxane-based Chemotherapies on the Pharmacokinetics of Drugs in Patients With Advanced Solid Tumor Malignancies

Solid Tumor Malignancies

United States
Antisoma Research

Completed

Study of AS1404 With Docetaxel in Patients With Hormone Refractory Metastatic Prostate Cancer

Prostate Cancer

United States
Cancer Research UK
Cancer Society Auckland

Completed

Study of DMXAA (Now Known as ASA404) in Solid Tumors (DMXAA)

Solid Tumors
Antisoma Research

Completed

Phase II Study of DMXAA (ASA404) in Combination With Chemotherapy in Patients With Advanced Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer
University of Memphis
University of Tennessee Health Science Center; USP Labs, Inc.

Completed

Pharmacokinetic Effects of Oral DMAA

Outcomes of Single Oral Dose

United States
University of California, San Francisco
Novartis Pharmaceuticals

Withdrawn

ASA404 in Combination With Carboplatin/Paclitaxel/Cetuximab in Treating Patients With Refractory Solid Tumors

Tumors

United States
Antisoma Research

Completed

Phase I Safety Study of DMXAA in Refractory Tumors (DART)

Refractory Tumors
Korean Pharmacoacupuncture Institute

Unknown

East-West Collaborative Medicine Using Bee-Venom Acupuncture on Whiplash-Associated Disorders

Whiplash Injuries
University of Pennsylvania

Recruiting

Phenotyping Genetic Risk for Type 2 Diabetes

Diabetes Mellitus, Type 2 | Genetics

United States
University Hospital, Strasbourg, France

Recruiting

Renal Function Assessment in the Elderly Using Plasma Creatinine Assay and Lean Body Mass Measurement (FREAGE)

Renal Function

France
Massachusetts General Hospital

Terminated

Pan-genotypic Direct Acting Antiviral Therapy in Donor HCV-positive to Recipient HCV-negative Lung Transplant

Hepatitis C | Respiratory Failure

United States
Hospital Mutua de Terrassa

Completed

Evaluation of the Safety and Effectiveness of Direct-acting Antiviral Drugs in the Treatment of Hepatitis C in Patients With Inflammatory Bowel Disease: National Multicenter Study (MIC project)

Inflammatory Bowel Diseases | Hepatitis C Virus Infection

Spain

3

Subscribe